SCHEMBL632573

SCHEMBL632573

Nc1scc2c1CN(C1CCCNC1=O)C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 10/20 0.40
IKZF3 Q9UKT9 2/20 0.40
BRD4 O60885 1/20 0.40
TNF P01375 1/20 0.40
IL1B P01584 1/20 0.40
IKZF1 Q13422 1/20 0.40
DDB1 Q16531 1/20 0.40
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
BTK Q06187 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 2/20 0.32
MEN1 O00255 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAP1LC3B Q9GZQ8 1/20 0.30
GAA P10253 1/20 0.30
PIK3R1 P27986 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL633819 1.00 CRBN (0.40) CRBNIKZF3BRD4TNFIL1B
SCHEMBL633567 1.00 CRBN (0.40) CRBNIKZF3BRD4TNFIL1B
SCHEMBL20288531 0.84 CRBN (0.54) CRBNIKZF3BRD4TNFIL1B
SCHEMBL20288757 0.84 CRBN (0.54) CRBNIKZF3BRD4TNFIL1B
SCHEMBL20263391 0.81 CRBN (0.35) CRBNIKZF3BRD4TNFIL1B
SCHEMBL20263390 0.81 CRBN (0.35) CRBNIKZF3BRD4TNFIL1B
SCHEMBL20263347 0.81 CRBN (0.35) CRBNIKZF3BRD4TNFIL1B
SCHEMBL634048 0.81 CRBN (0.62) CRBNIKZF3BRD4TNFIL1B
SCHEMBL20263354 0.81 CRBN (0.35) CRBNIKZF3BRD4TNFIL1B
SCHEMBL20263340 0.80 CRBN (0.34) CRBNIKZF3BRD4TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2093228-B1 PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF TIANJIN HEMAY BIO TECH CO LTD (CN) 2012-02-22 EP disclosed
US-20100152240-A1 PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF ZHANG HESHENG 2010-06-17 US disclosed
EP-2093228-A1 PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF Tianjin Hemey Bio-Tech Co., Ltd. (CN) 2009-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152240-A1 PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF TNF, IL1B, CYC1 CRBN 2750/4885IKZF3 2702/4885BRD4 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.